INNOVENT BIO (01801) releases its performance in 2025, with a net profit of 813.6 million yuan, achieving its first full-year profit.

INNOVENT BIO (01801) announced its annual performance as of December 31, 2025, with a total revenue of 13.415 billion yuan, a year-on-year increase of 38.4%; since the launch of its first product in 2019, the commercialization scale has rapidly expanded, fully reflecting the company's forward-looking strategic layout and efficient commercial execution capabilities. The company achieved its first full-year profit. Under the IFRS measurement, the net profit reached 813.6 million yuan. 2025 is a milestone year in the development history of INNOVENT BIO. The company has achieved historical breakthroughs in business scale, profitability, and global innovation, becoming a leading biopharmaceutical company with high growth potential and high certainty. As of the end of the year and up to the date of this announcement, the company has upgraded its "dual-drive" strategy, leading in the field of oncology, with the comprehensive product line contributing to new growth. The company has achieved a comprehensive positive turnaround in profit indicators, officially entering a new era of sustainable profitability. At the same time, three innovative assets are advancing to or about to enter global Phase III clinical development, and through multiple heavyweight strategic collaborations, accelerating the release of global pipeline innovation value, laying a solid foundation for the company to become a leading international biopharmaceutical company by 2030. The company's product portfolio has expanded to 18 marketed products, with 12 products included in the National Reimbursement Drug List (NRDL) in China. In the oncology field, the company has successfully launched several innovative products, including OYANING (erlotinib tablets), DABELU (gefitinib capsules), JIAPALI (pibrentasvir tablets), and DABIXIN (ipilimumab injection) - further consolidating the company's leading position in the field of cancer treatment in China. In the comprehensive product line, the company has successfully expanded its commercial map and created new growth pillars. XINERMEI (macitentan injection), XINBILE (torasemide injection), and XINBIN (tositumomab injection) have become key new growth engines. In addition, XINMEIYUE (pembrolizumab injection) as a cornerstone product in the field of self-immunology, was approved for market launch by the end of 2025. In addition, the new version of the NRDL catalog for 2025 (effective from January 1, 2026) includes a new indication for DABUSHU (sintilimab injection) and for the first time includes XINBIN (tositumomab injection), OYANING (erlotinib tablets), DABETE (fuzeredininib tablets), DABELU (gefitinib capsules), RUITUO (septerinin capsules) and JIAPALI (pibrentasvir tablets).